 |
Cambridge Isotope Laboratories, Inc.Cambridge Isotope Laboratories, Inc. (CIL) is the world’s leading producer of stable isotopes and stable isotope-labeled compounds. With over 400 employees and laboratories in four countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (nonradioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. Our chemists substitute common atoms (e.g., 1H, 12C, 14N, 16O) with rare, highly valued isotopes (e.g., 2H or D, 13C, 15N, 18O) so that the final product can be readily measured or traced using mass spectrometry (MS) or nuclear magnetic resonance (NMR). CIL’s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide. We are proud that CIL products have contributed to medical advancements in cancer research, new-drug development, environmental analysis, genomics and proteomics, and medical diagnostic research. In the past decade, as the fields of proteomics and metabolomics have developed as leading techniques for determining biomarkers for disease presence, progression and the monitoring of therapeutic response, CIL has worked closely with industry leaders and researchers to provide the stable isotope-labeled tools needed for improved quantitation of complex systems.3 Highwood Drive
Tewksbury, MA 01876
|
 |
RadSite326 First Street Suite 28
Annapolis, Maryland 21043
|
| |
| |
| |
| |
| |
| |
| |
|
KOELIS2020 Commonwealth Avenue
Auburndale, MA 02466,
United States
|
| |
| |
| |
|
Mirada MedicalOxford Centre for Innovation
New Road
Oxford, Oxfordshire, United Kingdom OX1 1BY
|
| |
| |
|
Neusoft MedicalNeusoft Medical Systems Co., Ltd (No.16 Shiji Road, Hunnan New District,Shenyang China)
Neusoft Medical Systems U.S.A., Inc (14425 Torrey Chase, Suite 100,Houston, TX 77014)
Neusoft Medical Middle East FZ-LLC (#501,Building 26,Al-Baker Building, Dubai Healthcare City, UAE)
|
| |
| |
|
NUCLEMEDNUCLEMED
't HOOG STUK 27
B-8800 ROESELARE - BELGIUM
|
| |
| |
| |
| |
| |
| |
| |
